Table 1.

Patients' characteristics (n = 100)

Characteristic	All patients (n = 100), n	HER2− (n = 89), n	HER2+ (n = 11), n	p value
Sex				.536
Male	55	50	5
Female	45	39	6
Age, median (range)	68 (33–84)	69 (35–84)	65 (33–79)	.561
ECOG PS				.854
0	55	51	4
1	38	34	4
2/3	7	4	3
Tumor grade				.698
G2	59	52	7
G3	36	33	3
Gx	5	4	1
Tumor site				.901
Intrahepatic	36	32	4
Extrahepatic	28	24	4
Ampullary	23	21	2
Gallbladder	13	12	1
Resection margins				1.000*
R0	94	83	11
R1	5	5	0
R2	1	1	0
T stage				.051
T1	19	18	1
T2	28	24	4
T3	49	44	5
T4	3	3	0
Tx	1	0	1
N stage				.379
N0	39	35	4
N1	40	37	3
Nx	21	17	4
Adjuvant chemotherapy				.201
Yes	50	47	3
No	50	42	8
Type of adjuvant treatment				1.000**
Gemcitabine	44	41	3
Capecitabine	4	4	0
Other regimens	2	2	0
Adjuvant radiotherapy				.515
Yes	4	4	0
No	96	85	11
Type of first‐line chemotherapy				.145a
Gemcitabine	12	9	3
Gemcitabine + platinum	22	19	3
Fluoropyrimidines	2	2	0
Fluoropyrimidines + platinum	8	8	0
Other regimens	6	6	0
Best supportive care	12	8	4
Not available	6	5	1

^aCombination treatment versus monotherapy versus best supportive care.

^* Radical resection versus R1/R2 Resection.

^** Gemcitabine versus others.

Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; G, grade.